

Roberto Bertollini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9931520/publications.pdf>

Version: 2024-02-01

43
papers

7,882
citations

172457

29
h-index

254184

43
g-index

75
all docs

75
docs citations

75
times ranked

8918
citing authors

#	ARTICLE	IF	CITATIONS
1	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	5.8	38
2	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	12.8	53
3	Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 799-800.	27.0	58
4	Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1091-1093.	27.0	83
5	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262897.	2.5	1
6	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1288-1290.	27.0	356
7	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	2.7	7
8	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	27.0	311
9	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	7
10	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	3.0	37
11	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	12.8	188
12	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	27.0	368
13	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	5.8	154
14	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	2.7	71
15	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	2.3	22
16	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	3.3	117
17	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.7	27
18	Steps and Challenges in Creating and Managing Quarantine Capacity During a Global Emergency – Qatar's Experience. <i>Journal of Infection and Public Health</i> , 2021, 14, 598-600.	4.1	4

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.9	58
20	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	4.3	74
21	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	69
22	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	7.1	153
23	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. <i>IScience</i> , 2021, 24, 102646.	4.1	79
24	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	3.3	14
25	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	30.7	337
26	Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 185.	7.4	37
27	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. <i>International Journal of Infectious Diseases</i> , 2021, 112, 52-54.	3.3	59
28	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	3.3	49
29	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. <i>International Journal of Infectious Diseases</i> , 2021, 110, 353-358.	3.3	74
30	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	49
31	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	27.0	675
32	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	7.4	140
33	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	30.7	346
34	Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. <i>New England Journal of Medicine</i> , 2021, 385, 2487-2489.	27.0	132
35	One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 768883.	3.9	56
36	Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. <i>New England Journal of Medicine</i> , 2021, 385, 2585-2586.	27.0	94

#	ARTICLE	IF	CITATIONS
37	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	8.4	54
38	The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. <i>BMC Infectious Diseases</i> , 2020, 20, 777.	2.9	41
39	Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 Februaryâ€“18 April 2020. <i>BMJ Open</i> , 2020, 10, e040428.	1.9	82
40	Impact of COVID-19 upon changes in emergency room visits with chest pain of possible cardiac origin. <i>BMC Research Notes</i> , 2020, 13, 539.	1.4	14
41	Volume and Acuity of Emergency Department Visits Prior To and After COVID-19. <i>Journal of Emergency Medicine</i> , 2020, 59, 730-734.	0.7	52
42	Protecting health in dry cities: considerations for policy makers. <i>BMJ, The</i> , 2020, 371, m2936.	6.0	5
43	The Lancet Commission on pollution and health. <i>Lancet, The</i> , 2018, 391, 462-512.	13.7	2,747